Idiopathic Pulmonary Fibrosis

12 · 20 / page

Ask MedXY AI

Latest news

Tag

newsEast Asian populationsgenetics

Shared Genetic Foundations of Idiopathic Pulmonary Fibrosis in East Asian and European Populations

By MedXY|Jul 11, 2026

Genetic risk loci for idiopathic pulmonary fibrosis (IPF) identified in East Asian populations largely overlap with those found in Europeans, though allele frequencies and effect sizes differ, highlighting shared ancestry and disease mechan

Quantitative CT Progression Thresholds in Idiopathic Pulmonary Fibrosis May Sharpen Annual Monitoring and Risk Stratification

newsfibrosis score

Idiopathic Pulmonary Fibrosis

Latest news

Shared Genetic Foundations of Idiopathic Pulmonary Fibrosis in East Asian and European Populations

Quantitative CT Progression Thresholds in Idiopathic Pulmonary Fibrosis May Sharpen Annual Monitoring and Risk Stratification

Nerandomilast in Idiopathic Pulmonary Fibrosis: Long-Term Insights from the FIBRONEER-IPF Trial

Nerandomilast Shows Potential Mortality Benefit in IPF Despite Neutral Composite Secondary Endpoints: Insights from FIBRONEER-IPF Extended Follow-up

Nerandomilast in IPF: Does Slowing Lung Function Decline Translate to Improved Survival?

Mapping the Preclinical Phase: The Conserved Sequence of Lung Function Decline in Idiopathic Pulmonary Fibrosis

Oral Nalbuphine Significantly Reduces Cough Frequency in Patients with Idiopathic Pulmonary Fibrosis: Results from the CORAL Trial

Taladegib Shows Potential to Improve Lung Function in Idiopathic Pulmonary Fibrosis: Results from the ENV-IPF-101 Phase 2a Trial

Dual αvβ6 and αvβ1 Integrin Inhibition Reduces Lung Collagen Deposition in Idiopathic Pulmonary Fibrosis: Insights from a Phase 2 Clinical Trial

Bexotegrast Shows Promise in Treating Idiopathic Pulmonary Fibrosis: Insights from the INTEGRIS-IPF Phase 2a Trial

Rentosertib: The First AI-Discovered TNIK Inhibitor Shows Promise in Idiopathic Pulmonary Fibrosis Phase 2a Trial

Nerandomilast for Idiopathic and Progressive Pulmonary Fibrosis: Phase 3 Trial Insights